Skip to content
The Policy VaultThe Policy Vault

VoqueznaHighmark

Relief of heartburn associated with non-erosive gastroesophageal reflux disease (NERD)

Preferred products

  • omeprazole
  • pantoprazole

Initial criteria

  • age ≥ 18 years
  • using Voquezna for relief of heartburn associated with non-erosive gastroesophageal reflux disease (ICD-10: K21.9)
  • experienced therapeutic failure, contraindication, or intolerance to all of the following plan-preferred products: omeprazole AND pantoprazole

Reauthorization criteria

  • continues to have a diagnosis of non-erosive gastroesophageal reflux disease which requires additional Voquezna therapy
  • prescriber attests the member has experienced symptom improvement or control during the initial 4-week treatment course
  • total treatment duration with Voquezna will not exceed 24 weeks in the past 365 days

Approval duration

initial: 4 weeks; reauthorization: 20 weeks